We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Body Surface Area Can Determine Success of Liver Transplantation

By HospiMedica International staff writers
Posted on 02 May 2013
A new study determines the safe range of deceased liver transplantation graft-size mismatch using body surface area index (BSAi).

Researchers at the University of Miami (FL, USA) and the University of Tokyo (Japan) conducted a study involving 24,509 patients to develop a multivariate survival model that can be used to estimate the hazard risk of BSAi for three-year graft survival, using data derived from the US national registry database between 2005 and 2010. More...
BSAi was calculated by dividing the BSA of the donor with the BSA of recipient.

The results showed that small-for-size grafts (BSAi less than 0.78) had a significant impact on graft dysfunction, with progressive increase of hazard risk towards the lowest end and a higher incidence of primary graft nonfunction and vascular thrombosis. On the other hand, large-for-size grafts (BSAi greater than 1.24) had a significant impact on graft dysfunction with progressive increase of hazard risk towards the largest end. The study was published ahead of print on April 10, 2013, in Transplant International.

“In live donor liver transplantation, rigorous standardized criteria for matching of liver volume between donor and recipient have prevented graft loss due to size mismatch,” concluded lead author Kyota Fukazawa, MD, and colleagues of the division of solid organ transplantation. “Therefore, BSAi higher than 0.78 and lower than 1.24 appears to be a safe range to avoid adverse outcome associated with size mismatch in deceased liver transplantation.”

In physiology and medicine, BSA is the measured or calculated surface of a human body. For many clinical purposes, BSA is a better indicator of metabolic mass than body weight because it is less affected by abnormal adipose mass. Examples of uses of BSA include renal clearance, usually divided by the BSA to gain an appreciation of the true required glomerular filtration rate (GFR); chemotherapy, often dosed according to the patient's BSA; and glucocorticoid dosing, expressed in terms of BSA for calculating maintenance doses.

Related Links:

University of Miami
University of Tokyo



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.